AATec 医学和北线生物技术伙伴开发一种新的支气管病治疗方法,ATL-105。 AATec Medical and Northway Biotech partner to develop a new treatment for bronchiectasis, ATL-105.

AATec医学和北线生物技术合作开发和扩大ATL-105的生产,这是对非CF支气管的新型治疗。 AATec Medical and Northway Biotech have partnered to develop and scale production of ATL-105, a novel treatment for non-CF bronchiectasis. 作为α-1抗素的复合版,ATL-105具有抗蛋白酶,抗炎症和抗感染的特性. ATL-105, a recombinant version of alpha-1 antitrypsin, combines anti-protease, anti-inflammatory, and anti-infective properties. 合作的目的是为临床和商业用途建立一个健全的生产流程,有可能为大量医疗需求未得到满足的呼吸道疾病提供新的治疗选择。 The collaboration aims to establish a robust production process for clinical and commercial use, potentially offering a new treatment option for respiratory diseases with significant unmet medical needs.